Skip to main content
TipRanks
Go Ultimate75% OFF

Utah Medical Products (UTMD) Stock Price & Analysis

123 Followers

UTMD Stock Chart & Stats

$72.36$0.39(0.54%)
At close: 4:00 PM EST
$67.5$70$72.5$75Aug 24Sep 8Sep 21Oct 5Oct 19Nov 2Nov 16
Day’s Range
$70.99 - $72.87
52-Week Range
$53.66 - $76.89
Previous Close
$71.97
Volume
N/A
Average Volume (3M)
37.04K
Market Cap
$206.19M
Enterprise Value
$150.46M
Total Cash (Recent Filing)
$85.20M
Total Debt (Recent Filing)
$180.00K
Price to Earnings (P/E)
21.7
Beta
0.41
Next Earnings
Feb 02, 2027 (Est.)
EPS Estimate
N/A
Dividend Yield
1.71%

Bulls Say, Bears Say

Bulls Say

Balance Sheet Strength

Minimal leverage materially reduces financial risk and preserves flexibility to fund operations, acquisitions, dividends, or buybacks without a meaningful debt burden. Stable equity and healthy ROE further support resilience if operating conditions remain soft.

Cash Generation

Strong operating and free cash flow, with FCF closely tracking earnings, indicates that reported profitability converts into usable funds. This supports internally funded investment and shareholder returns, although the lower level than past years warrants monitoring.

Orion Acquisition

Orion broadens UTMD’s presence in a specialized UK and European niche, adds expected annual sales, and is expected to be immediately accretive. Integration through existing Femcare facilities may create overhead efficiencies and reinforce targeted expansion.

Bears Say

Revenue Contraction

Revenue has declined materially over several years, indicating that the core business is not currently expanding. Persistent top-line contraction can reduce operating leverage, constrain reinvestment, and make future earnings growth harder to sustain.

Lower Free Cash Flow

Although cash generation remains solid, FCF has fallen from prior levels, reducing internally generated funding capacity. The decline signals that the revenue and earnings slowdown is affecting cash economics and could limit the pace of future investment or distributions.

Earnings Moderation

Profitability remains high, but earnings and FCF have stepped down from prior peaks alongside shrinking sales. If this persists, strong margins alone may not prevent lower absolute earnings, reducing the company’s ability to compound cash generation.

Utah Medical Products News

UTMD FAQ

What was Utah Medical Products’s price range in the past 12 months?
Utah Medical Products lowest stock price was $53.66 and its highest was $76.89 in the past 12 months.
What is Utah Medical Products’s market cap?
Utah Medical Products’s market cap is $206.19M.
When is Utah Medical Products’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Utah Medical Products’s earnings last quarter?
Utah Medical Products released its earnings results on Oct 22, 2026. The company reported $0.876 earnings per share for the quarter.
Is Utah Medical Products overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Utah Medical Products pay dividends?
Utah Medical Products pays a quarterly dividend of $0.315 which represents an annual dividend yield of 1.71%. See more information on Utah Medical Products dividends here
What is Utah Medical Products’s EPS estimate?
Utah Medical Products’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Utah Medical Products have?
Utah Medical Products has 2,849,541 shares outstanding.
What happened to Utah Medical Products’s price movement after its last earnings report?
Utah Medical Products reported an EPS of $0.876 in its last earnings report. Following the earnings report the stock price went up 0.455%.
Which hedge fund is a major shareholder of Utah Medical Products?
Hedge funds hold Utah Medical Products shares: the largest hedge-fund position in Utah Medical Products is 72,392,950 shares, and hedge funds increased their holdings by 38.0K shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology